PharmAust - Now that is impressive, page-109

I think I see where you are coming from TC. A Nasdaq listing will create shares thus create money for financing expected future R&D expenditure .

Back in 2016 ( I wasn’t on the register ) it seemed like RA was “ plugging “ the stock when the Nasdaq word was mentioned.

They signed of memory a MOU with a New York Investment Banker and that’s where it stands up to date.

In 2020 there are seven bio pharmaceutical stocks that have a listing in both Countries. I did own ATH (Alterity Pharmaceutical ) and if you look at their recent 6 month chart you will find some enormous up and down swings. I believe due to the secondary listing. ( at one stage ATH was called Prana and due to a bad result on a Phase 2 test on a Alzheimer’s cure the Nasdaq price dropped from $60 to $15 )

Many years ago I owned PRR a dual listing ( Prima Bio Med) it listed on the Nasdaq at maybe $7. But it slid down very quickly. As soon as a Nasdaq listing gets near a $1.50 the market jitters and it tends to fall in a hole. Minimum listing requirement is for the stock to stay over a dollar. ( if not the Company gets a please explain)

The other drama is the compliance.

But, conversely if PAA was to tick all the boxes in relation to Phase testings and for everything to absolutely go our way. Nasdaq and ASX would be rather complimentary.

My suggestion is to give RA an email and ask his thoughts. He knows the HC “ people” ask some pertinent questions.